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There is currently a trend in Western countries to increase the intake of plant 
proteins. In this chapter, the author explains that this is due to the beneficial physio-
logical functions of plant proteins, based on the latest literature review and our own 
research results. Among plant proteins, soy protein has been reported to have many 
beneficial effects on the improvement and prevention of metabolic syndrome. This 
chapter outlines the excellent effects of soy protein on renal function [improvement 
of early symptoms of diabetic nephropathy], which is closely related to metabolic 
syndrome, and the effects of combining these effects as complementary medicine. 
In addition, recent findings about the anti-inflammatory and immune activation 
effects of soy protein as hydrolyzed peptides are outlined. A brief introduction of 
the recent results of other legume-derived proteins that have replaced soy proteins 
are also explained. By further deepening our understanding of the superior physi-
ological functions of plant proteins, it is hoped that their use expands even further.
Keywords: soy protein, metabolic syndrome, chronic kidney disease, inflammatory 
disorder, pea protein, lupin protein, mung bean protein
1. Introduction
Protein is not only significant as an energy source, but also as a component of 
the body, such as muscle and connective tissue, and as a physiological function 
substance, such as enzymes, hormones, and immune antibodies.
On the other hand, the problem of food shortage (in particular, protein) due 
to global population growth is becoming increasingly serious. Because of the 
economic development of emerging countries, people who used to consume 
energy from “carbohydrates” such as bread and rice are now tending to consume 
“proteins” such as meat and seafood as a luxury item, and there are concerns about 
a shortage of protein supply on a global scale. Under these circumstances, the 
effective use of plant proteins as a protein source has been attracting attention. 
Plant proteins have been considered to be less adaptable to human tastes in terms 
of flavor and physical properties than animal proteins, but recent superior food 
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processing technologies have led to the marketing of “delicious” plant protein 
foods that are at the same level as animal protein foods.
It has been reported that plant proteins, especially soy proteins, have beneficial 
functions to improve and prevent lifestyle-related diseases that cannot be over-
come by animal proteins, which are currently prevalent all over the world. The 
US Food and Drug Administration [FDA] has approved the health claim for food 
labelling that the consumption of 25 g of soy protein per day reduces the risk of 
heart disease [1]. In Japan, the Consumer Affairs Agency [formerly the Ministry 
of Health, Labour and Welfare] has allowed the health labelling of soy protein as a 
food for specified health use “to people who are concerned about cholesterol levels” 
[FOSHU].
The beneficial physiological effects of soy protein are presumed to be due to 
anti-inflammatory properties. The anti-inflammatory effect of soy protein is 
enhanced by its processing into peptides. Indeed, it has been reported that soy 
peptides suppress muscle inflammation pain relief in rheumatoid arthritis and 
ameliorate inflammatory bowel disease.
Recently, it is being reported that not only soy proteins, but also some legume-
derived proteins have excellent physiological effects that are similar to, or even 
absent from, soy proteins. In this chapter, the author 1] introduces the beneficial 
physiological effects of soy protein for MetS, CKD and inflammation; 2] reports 
that these effects acted complementarily when used in combination with drugs; 
and 3] suggests other legume-derived proteins as alternatives to soy protein as novel 
proteins from legumes with beneficial physiological functions.
By understanding these findings, it is hoped that plant proteins will be used 
more actively to contribute to the improvement of human health, as well as their 
value as protein nutrition, which is in short supply worldwide.
2. Soy protein and peptides
2.1 Soy protein for metabolic syndrome (MetS)
The concept of MetS has been proposed by several committees. The first 
formalized concept of MetS was proposed by a consultation group for the defini-
tion of diabetes for the World Health Organization (WHO); it was determined to 
have a high-risk status with multiple risk factors for cardiovascular disease. This 
group emphasized insulin resistance as the major underlying factor [2]. In 2001, 
a definition for MetS was devised by the National Cholesterol Education Program 
(NCEP) Adult Treatment Panel III (ATP III) [3]. The American Heart Association 
and the National Heart Lung and Blood Institute updated this definition in 2005 
[4]. This updated definition is one of the most widely used criteria for MetS. The 
International Diabetes Foundation (IDF) published new criteria for MetS [5] in 
2005. Although it includes the same general criteria as the other definitions, it 
requires that obesity, but not necessarily insulin resistance, be present. Although 
visceral obesity is now recognized as an important factor, the IDF definition 
has been criticized for its emphasis on obesity, rather than insulin resistance, in 
pathophysiology [6].
In Japan, in 2006, MetS was defined as a multiple risk factor clustering syn-
drome caused by visceral fat accumulation and insulin resistance that accompanies 
this accumulation [7]. In the MetS stage, it is advocated that lifestyle intervention 
to reduce visceral adiposity should be given priority over drug treatment. Subjects 
with multiple risk factor syndrome were diagnosed with MetS if their visceral fat 
areas determined by CT scan were over 100 cm2.
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The Japanese Committee for the Definition and Diagnosis of MetS aimed to 
select subjects with multiple risk factors in which lifestyle modification to reduce 
visceral adiposity has priority over drug treatment [8]. For this purpose, the 
Japanese government started a new health policy that provides a specific health 
check-up followed by specific counseling for subjects diagnosed with MetS accord-
ing to the Japanese criteria from 2008.








Meta-analysis of the effects of 
soy protein intake on serum 
lipids.
38 743 Total-C↓, LDL-C↓, TG↓ [9]
Meta-analysis of the effects 
of soy protein containing 
isoflavones on the lipid 
profiles.
23 1,381 Total-C↓, LDL-C↓, 
TG↓, HDL-C↑
[10]
A meta-analysis of the 
effect of soy protein 
supplementation on serum 
lipids.




of soya proteins: result of 
recent studies are predictable 
from Anderson meta-analysis 
data.
27 923 Total-C↓, LDL-C↓ [12]
Soy protein effects on serum 
lipoproteins: a quality 
assessment and meta-analysis 
of randomized, controlled 
studies.
43 1,946 LDL-C↓, TG↓, HDL-C↑ [13]
Effect of Plant Protein on 
Blood Lipids: A Systematic 
Review and Meta-Analysis 










A Meta-Analysis of 46 
Studies Identified by the 
FDA Demonstrates that Soy 
Protein Decreases Circulating 
LDL and Total Cholesterol 
Concentrations in Adults.
43 2,607 Total-C↓, LDL-C↓ [15]
The effects of isolated 
soy protein, isolated soy 
isoflavones and soy protein 
containing isoflavones 
on serum lipids in 
postmenopausal women: 
A systematic review and 
meta-analysis.





Note: ↓ and ↑ signs represent decrease and increase, respectively, after supplement of active compounds. Total-
cholesterol (Total-C); low-density lipoprotein cholesterol (LDL-C); triglyceride (TG); high-density lipoprotein 
cholesterol (HDL-C); non-high-density lipoprotein cholesterol (non-HDL-C); apo-lipoprotein-B (Apo-B);  
apo-lipoprotein-AI (Apo-AI).
Table 1. 
Meta-analysis on improving lipid metabolism in soy protein.
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Soy protein exerts not only conventional nutritional value but also beneficial 
effects on human health. Many randomized controlled trials (RCTs) have assessed 
the effects of soy products on serum lipids. Systematic reviews and meta-analyses 
have reported improvements in lipid metabolism (Table 1) [9–16].
Soy protein isolate [SPI] is composed of three major components, glycinin 
[approx. 40%], β-conglycinin [approx. 20%], and lipophilic proteins (approx. 
40%) [17]. Glycinin and β-conglycinin are storage proteins in soy, and lipophilic 
proteins consist primarily of membrane proteins. Among these components, 
β-conglycinin has the function of lowering serum triglycerides preferentially 
over serum cholesterol [18]. Digestive decomposition products of β-conglycinin 
were reported that lowering the activity of fatty acid synthase and increasing 
the activities of β-oxidation enzymes, and the fecal excretion of TG was high 
in β-conglycinin-fed mice and rats [19, 20]. Therefore, in the calculation based 
on the recommendation by the FDA, the same effect can be expected with 5 g 
of β-conglycinin. In clinical study, daily consumption of 5 g of β-conglycinin 
per subject significantly lowered serum TG concentrations, and the apo B and 
VLDL-TG concentrations were significantly decreased [21]. Hence, β-conglycinin 
consumption may specifically affect TG metabolism. In addition, the intake of 
5 g of β-conglycinin per day decreased the body fat ratio and visceral fat [21, 22]. 
Additionally, serum adiponectin significantly increased with the consumption of 
β-conglycinin, and serum free fatty acids in the β-conglycinin group were signifi-
cantly decreased. Tachibana et al. showed that β-conglycinin improves insulin 
sensitivity in rats [23]. β-conglycinin might be an important food component for the 
prevention and/or amelioration of visceral fat syndrome, which is also called MetS 
(Table 2) [21, 22, 24–27].
2.2 Soy protein for chronic kidney disease
Chronic kidney disease [CKD] is a major public health burden, with a global 
prevalence of ~11% in the general adult population [28]. If left untreated, CKD 
slowly progresses to end-stage renal disease, which requires dialysis or kidney 
transplant. Worldwide, a 31.7% increase in CKD mortality was observed over the 
last decade [29]. Effective interventions to prevent and delay the progression of 
CKD are well recognized. Prevention should start at the government level with 
the institution of multisectoral polices supporting sustainable development goals 
[SDGs] and ensuring safe and healthy environments.
CKD is bidirectionally associated with MetS and cardiovascular diseases 
[CVDs] [30, 31], and diabetic nephropathy [DN] is a complication of diabetes [32]. 
Moreover, it has been reported that 40% of patients undergoing dialysis are doing 
so because of DN [33], and approximately 50% of type II diabetes patients exhibit 
urinary albumin disease, which is an early stage of DN [34].
For CKD prevention, it is important to gain insight about commonly consumed 
foods and beverages in relation to kidney function. A report has been published in 
which PubMed was comprehensively searched for papers published until August 
2019 describing prospective cohort studies and was supplemented by manual 
searches of reference lists from appropriate studies [35]. In this report, there 
was convincing evidence that a healthy dietary pattern may lower CKD risk. Red 
(processed) meat, poultry, fish, dairy, vegetables, legumes, nuts, and fruits were 
recommended foods for CKD patients. Dietary patterns were recommended adher-
ence to the Dietary Approach to Stop Hypertension (DASH) diet, Mediterranean 
diet, and other healthy dietary patterns. As unhealthy diets, high-fat and high-sugar 
diets and high-acid-loaded diets were pointed out. In the Atherosclerosis Risk in 
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Effects of soybean beta-conglycinin on body fat ratio and 




41 8-wk 4.4 g/day Body fat ratio↓ [22]
Serum triacylglycerol-lowering effect of soybean 





68 12-wk 2.3 g/day TG↓, HDL-C↑, Apo 
C-II↓
[24]





100 12-wk 2.3 g/4.6 g TG↓, LDL-C↓, 
Apo-B↓, NEFA↓
[25]





134 12-wk 38.8 g/week TG↓ [26]
Effects of beta-conglycinin intake on circulating FGF21 




21 2-wk 9.2 g/day FGF21↓, BAT act↑ [27]
Note: *1; Test 1 is an examination of the serum triglyceride level and Test 2 is a measure of visceral fat by means of CT scanning. ↓ and ↑ signs represent decrease and increase, respectively, after supplement 
of β-conglycinin. Triglyceride (TG); apo-lipoprotein-B (Apo-B); very low-density lipoprotein triglyceride (VLDL-TG); high-density lipoprotein cholesterol (HDL-C); apo-lipoprotein-CII (Apo-CII); 
low-density lipoprotein cholesterol (LDL-C); non-esterified fatty acid (NEFA); fibroblast growth factor 21 (FGF21); brown adipo tissue activity (BAT act).
Table 2. 
Clinical studies for lipid metabolism improvements of β-conglycinin.
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consumption of legumes was significantly associated with lower risks of CKD, with 
an HR of 0.83 [95% CI, 0.72; 0.95] for high versus low intakes [36]. Soy protein, 
which is representative of legumes, has been reported to suppress the progression of 
DN [37, 38]. The effects of soy protein on DN/CKD in clinical trials are summarized 
in Table 3 [39–43].
Kidney disease patients are carefully monitored for protein intake, and restricted 
protein intake according to the progression of their condition by doctors and nutri-
tionists. However, there are some reports showing that mild protein restriction does 
not suppress the progression of kidney disease [44–46]. Therefore, it is necessary to 
consider not only the quantity but also the quality of protein. Legumes, including soy 
protein, can be regarded as very significant proteins to help treat nephropathy.
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Note: ↓ sign represents decrease, after supplement of soy protein. Fasting plasma glucose [FPG]; total-cholesterol 
(Total-C); low-density lipoprotein cholesterol (LDL-C); C-reactive protein [CRP], blood urea nitrogen (BUN).
Table 3. 
Summary of clinical studies by soy protein for CKD.
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2.3 Anti-inflammatory roles of soy protein and peptides
Inflammation can occur when infectious microorganisms such as bacteria, 
viruses, and fungi invade the body and circulate in the blood, and/or when they enter 
certain tissues [47, 48]. Inflammation can also occur during the course of pathologies 
such as tissue damage, cell death, cancer, ischemia, and degeneration [49–51].
There are reports of the anti-inflammatory effects of soy protein and its 
hydrolysate peptides [52]. Among them, lunasin is considered one of the most 
studied bioactive peptides. Since its discovery in soybean twenty years ago, many 
researchers around the world have focused their studies on demonstrating the 
chemo preventive and chemotherapeutic activity of lunasin [53–55]. Lunasin 
is a 44 amino acid peptide isolated from soy that has three domains implicated 
in anticancer activity: an RGD motif [Arg-Gly-Asp], a helical domain with a 
sequence conserved in chromatin binding proteins [Glu-Lys-His-Ile-Met-Glu-
Lys-Ile], and a poly-aspartic acid tail [56]. Lunacin has been reported to have 
unique antioxidant, anti-inflammatory, and anti-cancer properties, and to play 
an important role in the regulation of cholesterol biosynthesis in the body [57]. 
Lunacin has potential as a dietary supplement by its high bioavailability and 
thermal stability.
Trypsin digests of soy proteins revealed that the sequence MITLAIPVNKPGR 
was able to stimulate phagocytosis in leukocytes. This peptide derived from 
β-conglycinin was named “Soymetide”. The Met at its N-terminus was essential for 
its activity [58]. Four residues of the C-terminal residues of Soymetide-13 could 
be removed to form Soymetide-9 [MITLAIPVN], which had the highest activity. 
In these 9 residues [Soymetide-9], Soymetide-4 [MITL] is the minimal sequence 
required for its activity [58].
Soy protein with or without isoflavones was shown to reduce oxidative stress and 
have anti-inflammatory properties by inhibiting nuclear factor-kappa B [NF-κB] 
and blocking the secretion of pro-inflammatory cytokines in model rats and mouse. 
In clinical study by subjects with end-stage renal disease and healthy women over 
70 years of age, their oxidative stress and inflammatory symptom were reduced 
[59]. The bioactive peptides RQRK and VIK were produced by digestion with pepsin 
and pancreatin from soy milk. These peptides inhibited lipopolysaccharide-induced 
inflammation in murine macrophages and the production of nitric oxide, interleu-
kin [I])-1, nitric oxide synthase, and cyclooxygenase-2 [60].
Inflammatory bowel disease [IBD] is an intractable disease that causes inflam-
mation of the gastrointestinal tract. Ulcerative colitis and Crohn’s disease are the 
two major pathologies of IBD [61]. Ulcerative colitis is a non-specific inflammatory 
disorder that causes ulcers and erosion, primarily in the colonic mucosa. Young 
et al. revealed that soy peptides were effective in preventing dextran sulphate 
sodium[(DSS)-induced colitis in pigs [62]. The soy-derived tripeptide Val-Pro-Tyr 
[VPY] has been reported that anti-inflammatory effects in Caco-2 and THP-1 mac-
rophages and inhibition of the secretion of IL-8 and TNF-α in a DSS-induced colitis 
model mouse [63]. They suggested that tripeptide VPY from soy peptides may be 
promising for the treatment of IBD.
Insulin resistance and diabetes has revealed to relate closely between nutri-
ent excess and activation of the innate immune system in most organs pertinent 
to energy homeostasis by the research for a mechanism linking the pathogenesis 
of obesity over the past two decades [64–66]. Inflammation has been revealed 
to occur as a consequence of obesity, and to play a causative role in generating 
insulin resistance, defective insulin secretion [i.e., MetS), and disruption of other 
aspects of energy homeostasis by recent many studies. It has been reported that the 
suppressive effect of soy protein on the progression of CKD/DN, which is highly 
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related to MetS, is also exerted by the anti-inflammatory effect in renal tubules 
[67]. From such a close relationship between MetS and inflammation, it is easy 
to predict that the beneficial effect of soy protein on MetS may be due to its anti-
inflammatory effect.
3.  Complementary effects of soy protein/peptide in combination with 
drugs
3.1 Effect of combined use with anti-hyperlipidaemic drugs
The mechanism by which soy protein lowers cholesterol differs from that of 
statins and fibrates. Soy protein lowers serum cholesterol levels by acting as a 
bile acid sequestrant, which binds bile in the gastrointestinal tract to prevent its 
reabsorption by performing the same anion exchange reaction as the resin  
cholestyramine [68, 69].
Statins and fibrates are drugs developed to improve blood lipid levels. Statins 
are known as the most efficient agents for reducing plasma cholesterol. Statins 
target hepatocytes and inhibit 3-hydroxy-3-methylglutaryl-coenzyme A [HMG-
CoA] reductase in cholesterol metabolism. Accordingly, statin and soy protein are 
expected to act additively or synergistically to decrease cholesterol levels. There 
are known serious side effects from statins, including muscle symptoms, rhab-
domyolysis [secondary renal failure due to destruction of specific muscle tissue], 
peripheral neuropathy, myopathy, liver dysfunction, and thrombocytopenia 
[70–73]. Rhabdomyolysis often induces sudden kidney failure [74]. Fibrates, which 
are antagonists of peroxisome proliferator-activated receptor α [PPARα], are used 
in adjunct therapy for hypertriglyceridemia and are usually used in combination 
with statins. As fibrate-related side effects, the slight gastric region discomfort and 
myopathy [myalgia with increased creatinine phosphokinase] have been reported. 
In addition, increasing of the gallstones risk has been known by fibrates because of 
increasing of cholesterol in the bile duct. Use in combination of statins and fibrates 
is reported to even more raise the risk of rhabdomyolysis. So, combination use of 
these two agents is contraindicated in principle.
Nabiki et al. examined the effects of SPI on weight loss, markers of diabetes, 
and parameters of dyslipidaemia in obese diabetic patients by treated with statins 
and/or fibrates because of high levels of LDL cholesterol and triglycerides [75]. As a 
result, body weights of these patients decreased significantly by approximately 1 kg 
and their waist circumferences got thinner significantly by approximately 2 cm. 
Total cholesterol, triglyceride, LDL cholesterol, apolipoprotein B, and glycated 
hemoglobin levels of these patients decreased significantly, and HDL cholesterol 
levels increased significantly. In addition, a lipid metabolism-improving effect was 
also observed in patients who did not decrease weight. Therefore, it was suggested 
that the improving effect of lipid metabolism-related factors in these patients was 
not only due to weight loss but also a direct effect of soy protein. Use of soy pro-
tein may help to reduce the drug dose for dyslipidaemia. SPI is recommended for 
patients with mild dyslipidaemia prior to drug therapy or for maladaptive disease 
patients, such as those who have side effects from medications.
Combination prescription of fibrates and statins for patients with renal dys-
function and dyslipidaemia is contraindicated. Thus, physicians are unable to 
adequately treat lipid abnormalities for chronic kidney disease patients. It has been 
reported that when chronic kidney disease patients with dyslipidaemia ingested 
β-conglycinin, a major component of soy protein, for 3 months, triglyceride and 
LDL cholesterol levels improved. Renal function during the consumption period 
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of β-conglycinin showed a tendency to improve despite protein intake [76]. 
β-conglycinin may help improve lipid abnormalities in patients with renal dysfunc-
tion as a complementary medical food material without decreasing kidney func-
tion. Moreover, β-conglycinin may improve renal dysfunction as a direct and/or 
secondary effect of ameliorating lipid abnormalities.
3.2 Concomitant effect with rheumatoid arthritis drug
Rheumatoid arthritis is due to inflammation triggered by an immune response 
to autoantigens. Many of these patients have swelling and pain due to polyarticu-
lar arthritis. Their pain interferes with activities of daily living [ADLs], such as 
cleaning, washing, dressing, and undressing. These patients are anxious for more 
comfortable ADLs with reduced pain. The mechanisms of onset of rheumatoid 
arthritis have been reported in many studies. Based on these results, numerous new 
therapeutic agents have been developed.
As a specific case of improved inflammation, outpatients with rheumatoid 
arthritis consumed soy peptide with therapeutic drugs and the levels of IL-6 and 
IL-1β were significantly lower in the soy peptide group than the placebo group 
[77]. An increase in blood IL-6 levels is associated with extra-articular symptoms 
of rheumatoid arthritis, such as general malaise, loss of appetite, weight loss, and a 
slight fever. The Disease Activity Score 28 [DAS 28, objective assessment of rheu-
matoid arthritis disease activity by physicians] and the Clinical Disease Activity 
Index [CDAI, patient’s own subjective indicator of rheumatoid arthritis disease 
activity] were calculated from the degree of ADLs’ improvement, the severity of 
pain, and subjective symptoms recorded by visual analogue scale [VAS]. The DAS 
28 score of the peptide group was markedly decreased, and the CDAI of the peptide 
group was significantly lower than that in the placebo group.
These effects on cytokines were also evident in a cell experiment using articular 
chondrocytes from patients with rheumatoid arthritis [78]. In this in vitro cell 
study, treatment with soy peptide significantly suppressed the mRNA levels of 
MMP-3 and ADAMTS-4 enhanced by IL-1β stimulation. This finding also suggests 
that soy peptides may prevent the degradation of articular cartilage.
4. Physiological effects of other legume proteins
Soy protein has excellent health benefits, but many soybeans grown in the world 
are genetically modified organisms [GMOs]. There is no problem with the safety of 
GMO soybeans. However, from the perspective of security, the use of soy protein 
in foods tends to be withheld. Recently, the use of pea and lupin proteins instead of 
soy protein has increased worldwide. Initially, pea protein was a substitute for soy-
bean protein as an ingredient with physical characteristics functions, after that, its 
beneficial health function has been reported mainly in sports nutrition. Mung bean 
protein has a structure very similar to that of β-conglycinin. Mung bean protein has 
been reported to be responsible for the beneficial physiological functions reported 
for β-conglycinin.
4.1 Pea protein
Field pea [Pisum sativum L.] is grown in 84 different countries and constitutes 
the largest percentage [36%] of total pulse production worldwide [79]. Global pea 
production has continuously increased over the last 30 years. In 2008, field pea was 
cultivated on over 10 million hectares worldwide with a total world production of 
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12.13 million tons [80]. The top 5 countries for pea production are Canada, Russia, 
China, India and the USA. The global market for pea protein is expected to reach 
34.8 million US dollars by 2020 [81]. The physical and chemical properties of pea 
protein can significantly influence its behaviors in food processing, storage and 
consumption [82, 83].
Life expectancy continues to increase worldwide. In the United States, adults 
65 years of age and older are projected to more than double from 600 million to 
1.6 billion worldwide between 2015 and 2050 [84]. Proper body composition, 
physical fitness, and a healthy appetite have been reported to lead to successful 
aging with higher performance [85, 86]. Skeletal muscle mass and strength begin 
to decline at age 30, and the rate of these losses accelerates at age 60 [87]. Protein 
ingestion strongly increases muscle protein synthesis rates [88]. Amino acids serve 
as precursors for de novo muscle protein synthesis and can act as strong signaling 
molecules activating translation initiation via the mechanistic/mammalian target of 
rapamycin complex-1 (mTORC1) pathway [89]. It was shown that BCAA ingestion 
increases myofibrillar protein synthesis rates during recovery from exercise only 
in young males [90]. Whey protein isolate [WPI] was used as the animal protein 
source because of its high concentration of BCAAs and its ability to increase satiety 
in response to a mixed meal [91]. While whey protein supplementation is known 
to enhance adaptations to resistance training, not all athletes are able or willing to 
consume whey or animal proteins. Vegetarian athletes who want to stick to a plant-
based diet or those with restrictions on other animal foods often rely on other plant 
proteins as an equivalent alternative to whey protein [92]. Self-identify as vegetar-
ian in just over 5% of U.S. adults aged 18–34 years and self-awareness as vegan in 
more than half of these respondents are reported in a 2016 Harris Poll conducted by 
the Vegetarian Resource Group [93]. Meat Free Mondays’ movement and an upsurge 
of plant-based protein food products in the marketplace strongly reflect the recent 
acceptance of these lifestyles [94].
Field pea contains a well-balanced amino acid profile [95]. Because of its avail-
ability, low cost, nutritional value and health benefits, pea protein has been widely 
used as a substitute for soybean or animal proteins in various functional applica-
tions [96–99]. Pea protein can also be used as a nutritional supplement for sports 
and exercises. Pea protein is an excellent source of BCAAs and has high and bal-
anced contents of leucine, isoleucine and valine. Indeed, there are reports that pea 
protein is as useful as whey protein in sports nutrition (Table 4) [100–103].
In the future, pea protein is expected to be widely used as a sports nutritional 
supplement as well as a physical and functional ingredient in place of soybean 
protein.
4.2 Lupin protein
Lupin (Lupinus L.) is an ancient pulse “bean” crop, and in the new genus of 
modern agriculture, the lupin seeds have great potential for high-protein food, 
animal feed, food potential, soil fertility improvement, plants as cover crops, crop 
residues as stable feed, and soil improvement [104, 105]. Lupin is well known for 
its ability to fix nitrogen and grow on infertile soils, and is further known to be 
valuable in terms of cropping rotations during the growing season in agriculture 
with cereals, hay, oilseeds, beans of other legumes, and disease break crops for 
pasture [104, 106]. Wild indigenous lupins have bitter alkaloids. All modern species 
of L. angustifolius have total alkaloid levels in seeds of up to 200 mg/kg [0.02%] 
or less, which is 100 times lower than the seed alkaloid levels of nearly wild types. 
Compared to almost all food crops, lupins have only recently become of interest in 
modern crop breeding.
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There has been considerable interest in lupin seeds recently, and as a human 
health food, the seeds are very high in dietary fiber, gluten-free, and virtually 
starch-free, and therefore have a very low glycemic impact [107]. What makes 
lupins even more valuable is that there are no genetically modified (GM) bean 
varieties under commercial cultivation. World production of lupin seed increased 
quickly in the 1970s and is dominated by Australian production.
Lupin seeds are high in protein, with levels similar to soybeans. Their grains 
are also known to be high in total dietary fiber, ~40 g/100 g dry matter, making 
lupins unique among ancient grains and beans. The main category of protein 
in lupin grains is globulin, with albumin making up the remainder. The major 
globulin categories are α-conglutin [35–37 g/100 g total protein], β-conglutin 
[44–45 g/100 g total protein], γ-conglutin [4–5 g/100 g total protein], and 
δ-conglutin [10–12 g/100 g total protein] [108–111]. Nutritionally, the limiting 
amino acids in lupin protein are the sulfur-containing amino acids methionine and 
cysteine [112]. Compared to soy protein, which have a more complete essential 
amino acid profile, the lupin protein was reported to be slightly below the required 
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Table 4. 
Clinical studies of pea protein for sports nutrition.
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level of sulfur-containing amino acids needed by adults [113]. However, Singla 
et al. reported that the sulfur-containing amino acid levels of lupin protein were 
similar to those of soy [114]. This discrepancy is probably due to differences in lupin 
protein varieties and production environments. Carvajal-Larenas et al. reviewed 
in detail the amino acid composition of whole lupin seeds and concluded that it 
varies slightly among species. In vitro digestibility is ~98% high for uncooked lupin 
protein and is similar to soybean [115].
In vitro models of Lupinus albus γ-conglutin have shown the biological activity 
that enhances insulin and metformin activity on intracellular glucose consumption, 
indicating the potential for regulation on blood glucose by γ-conglutin [116]. As 
a possible improvement of lipid metabolism, an increase in LDL receptor activity 
has been demonstrated by HepG2 cells [117]. Furthermore, isolated lupin proteins 
of have been reported to have hyperlipidemic, anti-atherogenic, and hypocholes-
terolemic effects in rabbits, rats, and chickens [118, 119]. Several clinical human 
studies have shown that lupin protein decreases total and LDL cholesterol, as well as 
triglyceride and reduce the glycaemic response (Table 5) [120–127].
In general, the anti-nutrient factor of lupins is considered to be low compared to 
other legumes such as soybeans. Specifically, protease inhibitors are present at very 
low levels and are of minor importance in lupin crops. Trypsin inhibitor activity is 
described as “negligible” in Lupinus species, “very strong” at 43–84 trypsin inhibi-
tor units [TIU/mg] in soybeans, and high [17–51 TIU/mg] in common beans [128]. 
Bitter lupin seed varieties contain quinolizine alkaloids, which may be toxic to 
humans. These toxic effects were recently reviewed by Carvajal-Larenes et al. [115]. 
Therefore, its maximum legal level of 0.02 g/100 g lupine powder and food has 
been legislated in several countries. There were no differences in alkaloids in grains 
among commercial L. angustifolius cultivars from western Australia in the same 
region and season, and all samples were below the levels permitted for maximum 
human food use.
Lupin protein, a legume, is a plant protein with similar attributes to soybean 
protein [129] and can be a substitute for soybean in the food industry [130, 131]. 
Further extensive research is expected due to the need for alternatives to animal 
proteins.
4.3 Mung bean protein
The mung bean (Vigna radiata L.) is one of the most important edible legume 
crops, grown on more than 6 million ha worldwide (approximately 8.5% of the 
global pulse area) and consumed by most households in Asia [132]. For individu-
als who cannot afford animal proteins or those who are vegetarian, mung bean is 
comparatively low cost and is a good source of protein. Furthermore, mung bean 
protein is more easily digestible than protein in other legumes [133]. In addition to 
the nutritional properties of mung bean, it has been known that mung beans have 
various physical regulation functions from ancient times. In the Compendium of 
Materia Medica (the “Bencao Gangmu”), a well-known Chinese pharmacopeia, 
mung beans have recorded to be utilized as a traditional Chinese medicine for its 
detoxification activities, recuperation of mentality, ability to alleviate heat stroke, 
and regulation of gastrointestinal upset.
Mung bean protein isolate (MuPI) dose-dependently reduced plasma lipid 
levels, such as total cholesterol, triglycerides, and non-high-density lipoprotein 
cholesterol [non-HDL-C] in hamsters [134, 135]. The mechanism underlying the 
cholesterol-lowering activity of mung bean protein was speculated to increase fecal 
bile acid and sterol excretion and decrease cholesterol absorption and synthesis. 
This mechanism is the same as that reported for SPI [68, 69]. In another study, 
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cholesterol (Total-C); low-density lipoprotein cholesterol (LDL-C); triglyceride (TG); high-density lipoprotein 
cholesterol (HDL-C).
Table 5. 
Clinical studies of lupin protein on improving lipid and glucose metabolisms.
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MuPI was found to lower blood triglyceride levels in normal rats by inducing 
adiponectin and reducing triglyceride synthesis via insulin signaling [136]. This 
mechanism is the same as that reported for β-conglycinin [23]. From these findings, 
MuPI can be expected to be more effective in improving lipid metabolism. The 
main component of MuPI, accounting for over 80% of the protein, is 8S globulin. 
8S globulin exhibited the highest degree of sequence identity [68%] and structural 
similarity with β-conglycinin [137, 138]. MuPI is expected to exhibit a four times 
stronger beneficial function on human health than SPI, in which β-conglycinin 
accounts for only 20% of the total protein.
The positive effects of MuPI on glucose metabolism in pre-diabetes patients 
was confirmed. In recent double-blind, placebo-controlled clinical trial, the test 
group subjects were instructed to consume a total of 2.5 g of MuPI twice daily for 
12 weeks, with pre-diabetes [fasting plasma glucose level of 110–125 mg/dL or 2-h 
plasma glucose level of 140–200 mg/dL by the 75-g glucose tolerance test]. In this 
study, MuPI was shown to suppress to increase fasting plasma glucose and insulin 
levels compared to the placebo group. Triglyceride levels significantly decreased 
in subjects with hyperlipidaemia [139]. Another double-blind, placebo-controlled 
clinical trial of 44 healthy subjects showed that after consumption of 3.0 g/d MuPI 
for 8 weeks, insulin levels and homeostatic model assessment of insulin resistance 
values significantly decreased, and plasma glucose levels showed a downtrend, 
although it was not significant [140]. The lack of a beneficial effect of MuPI on 
blood glucose concentrations may be attributed to the exclusion of volunteers with 
abnormal blood glucose concentrations in this study. In this study, the body compo-
sitions of subjects were measured by dual-energy X-ray absorptiometry. As a result, 
a decrease in body fat mass and an increase in lean body mass in the test group were 
revealed. Conversely, in the control group, body fat mass increased and lean body 
mass decreased. The differences in body fat mass and lean body mass within each 
group and between the test and control groups were not statistically significant. 
However, the adiponectin level in the test group significantly increased, and it 
decreased in the control group. There was a significant difference between the net 
changes in the test and control groups [140]. These findings indicate that MuPI 
might improve insulin sensitivity by decreasing the accumulation of visceral fat.
Non-alcoholic fatty liver disease [NAFLD] represents a spectrum of liver diseases 
involving hepatocyte dysfunction caused by hepatic triglyceride accumulation in 
these cells. The prevalence of NAFLD has increased with the increased prevalence of 
obesity and metabolic syndrome. NAFLD is now a common disease, affecting 30% of 
the US population and 20% of Asian and European populations [141]. Rodent studies 
have shown that SPI intake reduces hepatic triglyceride accumulation [142, 143]. The 
detailed mechanism underlying the hepatic triglyceride-reducing effect of SPI remains 
to be elucidated, but β-conglycinin is likely to play an important role [135]. Indeed, 
the administration of purified β-conglycinin results in an even stronger reduction 
in hepatic triglycerides than SPI administration [18, 144]. From these results, it is 
expected that MuPI also has a preventive effect on NAFLD by preventing hepatic 
triglyceride accumulation. The effect of MuPI on hepatic triglyceride accumulation 
elucidated the potential ability of MuPI to prevent NAFLD onset and progression in 
experiments using an atherogenic diet-induced NASH mouse model in mice fed a 
normal-fat or high-fat diet [145]. In the abovementioned clinical trial [140], Alanine 
aminotransferase [ALT] levels increased slightly in the control group, whereas signifi-
cantly decreased in the test group. Of the blood test items, ALT is one of important 
indicators of the degree of liver dysfunction.
The released peptides obtained from mung bean protein hydrolysate may 
exhibit bioactivity as angiotensin I-converting enzyme (ACE) inhibitors, 
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antioxidants, and anti-cancer Asiatic acid carriers due to their sequence charac-
teristics [146, 147]. A peptide [<3 kDa], with a small molecular weight isolated 
from MuPI hydrolysates, was reported to show high ACE inhibitory and antioxi-
dant activities, including DPPH radical scavenging activity, hydroxyl radical scav-
enging ability, and metal-chelating activity [146]. Three kinds of novel peptides 
exerting high ACE inhibitory activity were isolated from the alcalase hydrolysate 
of MuPI, and the amino acid sequences of these peptides were identified to be 
Lys-Asp-Tyr-Arg-Leu, Val-Thr-Pro-Ala-Leu-Arg, and Lys-Leu-Pro-Ala-Gly-Thr-
Leu-Phe [148].
The relationships between MuPI intake, strength, and lean body mass (LBM) in 
underactive vegetarians were examined, and the impact of MuPI supplementation 
on these indices was recorded utilizing an eight-week, randomized, controlled feed-
ing trial. LBM significantly correlated with grams of protein consumed daily and 
was also significantly correlated with grip strength and lower body strength [149]. 
Mung beans are inadequate in threonine, tryptophan, and the sulfur-containing 
amino acids cysteine and methionine, but they contain high levels of essential 
amino acids, notably leucine, lysine, and phenylalanine [150]. Although it is neces-
sary to consider the amino acid balance, it is expected that MuPI will be widely used 
in the field of sports nutrition in the future.
5. Conclusion
If the current pace of population growth continues, the global population is 
expected to surpass 9 billion by 2050. In addition to this increase in population, 
the change of dietary habits of emerging countries due to their increased GDP will 
require, in 2050, we will need twice as much protein as we had in 2005.
So far, we have been able to meet the increasing demand for protein by improv-
ing the productivity of agriculture. However, in the future, this growth alone will 
not be enough to absorb the increase, and the balance between supply and demand 
will begin to collapse as early as 2030. This prediction is called the “protein crisis,” 
and has recently begun to attract attention, especially in Europe and the United 
States. To solve this protein crisis, it is essential to use highly productive plant 
proteins as food ingredients instead of animal proteins, which are less efficient in 
production.
WHO has called for the need to address the double burden of malnutrition. This 
means that we need to look not only at nutrient deficiencies, but also at nutri-
ent excesses. Obesity caused by over-nutrition and the resulting lifestyle-related 
diseases are spreading around the world. In this regard, consumer demand for 
plant protein-based products is high and expected to grow considerably in the next 
decade. A variety of soy and other plant-based functional foods have been recom-
mended by many health organizations worldwide.
Currently, contributions to the SDGs (Sustainable Developing Goals) are being 
appealed around the world. There is widespread recognition that the replacement 
of animal protein with vegetable protein not only contributes to human health, 
but also to the earth health. Wider and prudent use of plant proteins in the diet can 
help to supply adequate high-quality protein for the population and may reduce the 
potential for adverse environmental consequences.
This chapter focused on the recently reported physiological functions of 
legumes-derived plant proteins, including soybeans. Further research is expected to 
lead to more widely use of the legumes introduced in this chapter and to the discov-
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